Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis August 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference August 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results August 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) June 28, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results May 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand April 30, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers ASX:CSL CSLLY SPRY ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) April 03, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day March 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 March 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study February 26, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024 February 22, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter February 20, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting February 05, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates November 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis November 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray) October 06, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology October 03, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study September 19, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates August 10, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis June 20, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results May 15, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis May 11, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis May 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis March 28, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results March 23, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SPRY ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors February 23, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis February 22, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SBTX SPRY ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 February 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SBTX SPRY ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis November 10, 2022 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Tickers SBTX SPRY ARS Pharmaceuticals Announces FDA Acceptance of NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis October 21, 2022 From ARS Pharmaceuticals, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.